Clearmind Medicine (CMND)
3.98
+1.07 (36.77%)
Upcoming Events
Latest Headlines
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
June 5, 2026 7:32 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: Jun 01
June 1, 2026 4:07 PM - SEC Filing
Clearmind Medicine files Japanese patent for depression treatment compound
May 29, 2026 8:41 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: May 29
May 29, 2026 8:35 AM - SEC Filing
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
May 29, 2026 8:32 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: May 26
May 26, 2026 8:30 AM - SEC Filing
Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts
May 26, 2026 8:25 AM - StreetInsider
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
May 26, 2026 8:25 AM - Globe NewsWire
Form 6-K Clearmind Medicine Inc. For: May 19
May 19, 2026 6:52 AM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: May 19
May 19, 2026 6:21 AM - SEC Filing
Clearmind Medicine announces 1-for-10 reverse stock split effective May 21
May 19, 2026 6:00 AM - StreetInsider
Clearmind Medicine Announces 1-for-10 Reverse Share Split
May 19, 2026 6:00 AM - Globe NewsWire
Form 6-K Clearmind Medicine Inc. For: May 18
May 18, 2026 4:06 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: May 18
May 18, 2026 4:01 PM - SEC Filing
Clearmind Medicine signs research deal to study MEAI with tirzepatide
May 18, 2026 8:42 AM - StreetInsider
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
May 18, 2026 8:42 AM - Globe NewsWire
Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: L.I.A. Pure Capital Ltd
May 15, 2026 4:23 PM - SEC Filing
Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: Capitalink Ltd.
May 15, 2026 4:22 PM - SEC Filing
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
May 15, 2026 8:35 AM - Globe NewsWire
Form 6-K Clearmind Medicine Inc. For: May 12
May 12, 2026 9:28 AM - SEC Filing
Clearmind Medicine doses 20th participant in alcohol disorder trial
May 12, 2026 8:41 AM - StreetInsider
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
May 12, 2026 8:41 AM - Globe NewsWire
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
May 11, 2026 7:55 AM - Globe NewsWire
Form EFFECT Clearmind Medicine Inc.
May 8, 2026 6:09 AM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: May 05
May 5, 2026 8:53 AM - SEC Filing
Clearmind Medicine files European patent application for PTSD compounds
May 5, 2026 8:53 AM - StreetInsider
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
May 5, 2026 8:50 AM - StreetInsider
Form F-3 Clearmind Medicine Inc.
April 30, 2026 4:28 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Apr 30
April 30, 2026 4:19 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Apr 27
April 27, 2026 7:45 AM - SEC Filing
Clearmind Medicine evaluates psychedelic drug for FDA breakthrough status
April 27, 2026 7:41 AM - StreetInsider
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
April 27, 2026 7:41 AM - Globe NewsWire
Form 6-K Clearmind Medicine Inc. For: Apr 21
April 21, 2026 6:57 AM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Apr 20
April 20, 2026 5:18 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Apr 20
April 20, 2026 4:05 PM - SEC Filing
Clearmind Medicine responds to Trump executive order on psychedelic drugs
April 20, 2026 4:03 PM - StreetInsider
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
April 20, 2026 4:03 PM - StreetInsider
Clearmind Medicine meets safety endpoint in alcohol disorder trial
April 20, 2026 7:15 AM - StreetInsider
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
April 20, 2026 7:15 AM - Globe NewsWire
Form 6-K Clearmind Medicine Inc. For: Apr 15
April 15, 2026 9:16 AM - SEC Filing
Clearmind Medicine gets safety board approval to continue alcohol disorder trial
April 15, 2026 7:31 AM - StreetInsider
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
April 15, 2026 7:30 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: Apr 15
April 15, 2026 7:01 AM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Apr 14
April 14, 2026 4:01 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Apr 14
April 14, 2026 8:23 AM - SEC Filing
Clearmind Medicine's CMND-100 meets primary endpoint in phase trial
April 14, 2026 7:32 AM - StreetInsider
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
April 14, 2026 7:32 AM - Globe NewsWire
Form EFFECT Clearmind Medicine Inc.
March 31, 2026 6:20 AM - SEC Filing
Form EFFECT Clearmind Medicine Inc.
March 31, 2026 6:20 AM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Mar 30
March 30, 2026 9:27 AM - SEC Filing
Clearmind Medicine completes treatment for 18 participants in phase 1 trial
March 30, 2026 8:32 AM - StreetInsider
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
March 30, 2026 8:32 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: Mar 27
March 27, 2026 7:40 AM - SEC Filing
Clearmind Medicine files patent application in India for psychedelic compounds
March 27, 2026 7:32 AM - StreetInsider
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
March 27, 2026 7:32 AM - StreetInsider
Form POS AM Clearmind Medicine Inc.
March 25, 2026 4:17 PM - SEC Filing
Form POS AM Clearmind Medicine Inc.
March 25, 2026 4:15 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Mar 19
March 19, 2026 4:01 PM - SEC Filing
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
March 19, 2026 8:45 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: Mar 17
March 17, 2026 9:17 AM - SEC Filing
Clearmind Medicine secures six Hong Kong patents for psychedelic combinations
March 17, 2026 9:15 AM - StreetInsider
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
March 17, 2026 9:15 AM - StreetInsider
Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: L.I.A. Pure Capital Ltd
March 16, 2026 11:12 AM - SEC Filing
Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: Capitalink Ltd.
March 16, 2026 10:18 AM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Mar 13
March 13, 2026 7:47 AM - SEC Filing
Clearmind Medicine files Hong Kong patent for depression therapy combo
March 13, 2026 7:46 AM - StreetInsider
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026 7:45 AM - Globe NewsWire
Form 6-K Clearmind Medicine Inc. For: Jan 31
March 12, 2026 4:18 PM - SEC Filing
Form 6-K Clearmind Medicine Inc. For: Mar 11
March 11, 2026 4:01 PM - SEC Filing
Clearmind Medicine advances CMND-100 trial enrollment following positive results
March 11, 2026 9:08 AM - StreetInsider
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
March 11, 2026 9:07 AM - Globe NewsWire
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
March 11, 2026 9:07 AM - StreetInsider
Form 6-K Clearmind Medicine Inc. For: Mar 10
March 10, 2026 9:30 AM - SEC Filing
Clearmind Medicine receives international patent for weight loss therapy
March 10, 2026 8:59 AM - StreetInsider
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 10, 2026 8:59 AM - StreetInsider
Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: Daniel Nissim
March 9, 2026 4:30 PM - SEC Filing
Full Article List
